Clinical Characteristics of Rapidly Progressive Fatal Hemorrhagic Pneumonia Caused by Stenotrophomonas maltophilia
Objective Hemorrhagic pneumonia due to Stenotrophomonas maltophilia (SM) in severely immunocompromised patients has a very poor prognosis. However, the risk factors for hemorrhagic pneumonia are not clear. Methods This study assessed the predictive factors of hemorrhagic pneumonia caused by SM. The...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2020/01/15, Vol.59(2), pp.193-198 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 198 |
|---|---|
| container_issue | 2 |
| container_start_page | 193 |
| container_title | Internal Medicine |
| container_volume | 59 |
| creator | Imoto, Waki Yamada, Koichi Yamairi, Kazushi Shibata, Wataru Namikawa, Hiroki Yukawa, Satomi Yoshii, Naoko Nakaie, Kiyotaka Hirose, Asao Koh, Hideo Watanabe, Tetsuya Asai, Kazuhisa Nakamae, Hirohisa Kaneko, Yukihiro Kawaguchi, Tomoya Hino, Masayuki Kakeya, Hiroshi |
| description | Objective Hemorrhagic pneumonia due to Stenotrophomonas maltophilia (SM) in severely immunocompromised patients has a very poor prognosis. However, the risk factors for hemorrhagic pneumonia are not clear. Methods This study assessed the predictive factors of hemorrhagic pneumonia caused by SM. The medical records of patients admitted to Osaka City University Hospital with SM bacteremia between January 2008 and December 2017 were retrospectively reviewed. Patients All patients who had positive blood cultures for SM were included in this study. They were categorized into two groups: the SM bacteremia with hemorrhagic pneumonia group and the SM bacteremia without hemorrhagic pneumonia group. The clinical background characteristics and treatments were compared between these groups. Results The 35 patients with SM bacteremia included 4 with hemorrhagic pneumonia and 31 without hemorrhagic pneumonia. Hematologic malignancy (p=0.03) and thrombocytopenia (p=0.04) as well as the prior use of quinolone within 30 days (p=0.04) were more frequent in the SM bacteremia patients with hemorrhagic pneumonia than in those without hemorrhagic pneumonia. The mortality of the SM bacteremia patients with hemorrhagic pneumonia was higher than that of those without hemorrhagic pneumonia group (p=0.02). Conclusion Patients with SM bacteremia who have hematologic malignancy, thrombocytopenia, and a history of using quinolone within the past 30 days should be treated with deliberation. |
| doi_str_mv | 10.2169/internalmedicine.3358-19 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7008057</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2349871760</sourcerecordid><originalsourceid>FETCH-LOGICAL-c666t-bfdfadea3583167dac10836a45e2e096a75829b1e59f4c3293d1c6c4398e5f743</originalsourceid><addsrcrecordid>eNplkk1v1DAQhiMEokvhLyBLXLikteMkji9IKKIUqSoVH2dr1pnseuXYi-1U2n-Po11WUC4zsuaZ1555XRSE0auKtfLauITBgZ1wMNo4vOK86UomnxUrxmtZioo3z4sVlawrqxwuilcx7ijlnZDVy-KCM1mzrpWrIvTWOKPBkn4LAXTWNTEZHYkfyTfYm8EeyEPwm4AxmkckN5AyfIuTD2ELG6PJg8N58s4A6WGOOJD1gXxP6HwKfr_1uQSRTGBTPhlr4HXxYgQb8c0pXxY_bz796G_Lu6-fv_Qf70rdtm0q1-MwwoCQJ-OsFQNoRjveQt1ghVS2IJqukmuGjRxrzSvJB6ZbXXPZYTOKml8WH466-3mdF6XRpQBW7YOZIByUB6P-rTizVRv_qASlHW1EFnh_Egj-14wxqclEjdaCQz9HVXEuhaS84Rl99wTd-XlxaKFq2QkmWpqp7kjp4GMMOJ4fw6hajFVPjVWLsYrJ3Pr272HOjX-czMD9EdjFBBs8AxCymxb_V26kqpZwuuEM6vwPFDr-GwdIxPk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2349871760</pqid></control><display><type>article</type><title>Clinical Characteristics of Rapidly Progressive Fatal Hemorrhagic Pneumonia Caused by Stenotrophomonas maltophilia</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>PubMed Central</source><creator>Imoto, Waki ; Yamada, Koichi ; Yamairi, Kazushi ; Shibata, Wataru ; Namikawa, Hiroki ; Yukawa, Satomi ; Yoshii, Naoko ; Nakaie, Kiyotaka ; Hirose, Asao ; Koh, Hideo ; Watanabe, Tetsuya ; Asai, Kazuhisa ; Nakamae, Hirohisa ; Kaneko, Yukihiro ; Kawaguchi, Tomoya ; Hino, Masayuki ; Kakeya, Hiroshi</creator><creatorcontrib>Imoto, Waki ; Yamada, Koichi ; Yamairi, Kazushi ; Shibata, Wataru ; Namikawa, Hiroki ; Yukawa, Satomi ; Yoshii, Naoko ; Nakaie, Kiyotaka ; Hirose, Asao ; Koh, Hideo ; Watanabe, Tetsuya ; Asai, Kazuhisa ; Nakamae, Hirohisa ; Kaneko, Yukihiro ; Kawaguchi, Tomoya ; Hino, Masayuki ; Kakeya, Hiroshi</creatorcontrib><description>Objective Hemorrhagic pneumonia due to Stenotrophomonas maltophilia (SM) in severely immunocompromised patients has a very poor prognosis. However, the risk factors for hemorrhagic pneumonia are not clear. Methods This study assessed the predictive factors of hemorrhagic pneumonia caused by SM. The medical records of patients admitted to Osaka City University Hospital with SM bacteremia between January 2008 and December 2017 were retrospectively reviewed. Patients All patients who had positive blood cultures for SM were included in this study. They were categorized into two groups: the SM bacteremia with hemorrhagic pneumonia group and the SM bacteremia without hemorrhagic pneumonia group. The clinical background characteristics and treatments were compared between these groups. Results The 35 patients with SM bacteremia included 4 with hemorrhagic pneumonia and 31 without hemorrhagic pneumonia. Hematologic malignancy (p=0.03) and thrombocytopenia (p=0.04) as well as the prior use of quinolone within 30 days (p=0.04) were more frequent in the SM bacteremia patients with hemorrhagic pneumonia than in those without hemorrhagic pneumonia. The mortality of the SM bacteremia patients with hemorrhagic pneumonia was higher than that of those without hemorrhagic pneumonia group (p=0.02). Conclusion Patients with SM bacteremia who have hematologic malignancy, thrombocytopenia, and a history of using quinolone within the past 30 days should be treated with deliberation.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.3358-19</identifier><identifier>PMID: 31941869</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>Adult ; Bacteremia ; Female ; Gram-Negative Bacterial Infections - complications ; Gram-Negative Bacterial Infections - drug therapy ; Hematologic Neoplasms - complications ; Hemoptysis - microbiology ; Hemorrhage ; Hemorrhage - microbiology ; hemorrhagic pneumonia ; Humans ; Immunocompromised Host ; Immunocompromised hosts ; Internal medicine ; Male ; Malignancy ; Medical records ; Middle Aged ; Original ; Patients ; Pneumonia ; Pneumonia, Bacterial - complications ; Pneumonia, Bacterial - drug therapy ; Prognosis ; quinolone ; Quinolones - therapeutic use ; Retrospective Studies ; Risk Factors ; Stenotrophomonas maltophilia ; Stenotrophomonas maltophilia - immunology ; Thrombocytopenia ; Thrombocytopenia - complications ; Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use</subject><ispartof>Internal Medicine, 2020/01/15, Vol.59(2), pp.193-198</ispartof><rights>2020 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2020</rights><rights>Copyright © 2020 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c666t-bfdfadea3583167dac10836a45e2e096a75829b1e59f4c3293d1c6c4398e5f743</citedby><cites>FETCH-LOGICAL-c666t-bfdfadea3583167dac10836a45e2e096a75829b1e59f4c3293d1c6c4398e5f743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008057/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008057/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1883,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31941869$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Imoto, Waki</creatorcontrib><creatorcontrib>Yamada, Koichi</creatorcontrib><creatorcontrib>Yamairi, Kazushi</creatorcontrib><creatorcontrib>Shibata, Wataru</creatorcontrib><creatorcontrib>Namikawa, Hiroki</creatorcontrib><creatorcontrib>Yukawa, Satomi</creatorcontrib><creatorcontrib>Yoshii, Naoko</creatorcontrib><creatorcontrib>Nakaie, Kiyotaka</creatorcontrib><creatorcontrib>Hirose, Asao</creatorcontrib><creatorcontrib>Koh, Hideo</creatorcontrib><creatorcontrib>Watanabe, Tetsuya</creatorcontrib><creatorcontrib>Asai, Kazuhisa</creatorcontrib><creatorcontrib>Nakamae, Hirohisa</creatorcontrib><creatorcontrib>Kaneko, Yukihiro</creatorcontrib><creatorcontrib>Kawaguchi, Tomoya</creatorcontrib><creatorcontrib>Hino, Masayuki</creatorcontrib><creatorcontrib>Kakeya, Hiroshi</creatorcontrib><title>Clinical Characteristics of Rapidly Progressive Fatal Hemorrhagic Pneumonia Caused by Stenotrophomonas maltophilia</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>Objective Hemorrhagic pneumonia due to Stenotrophomonas maltophilia (SM) in severely immunocompromised patients has a very poor prognosis. However, the risk factors for hemorrhagic pneumonia are not clear. Methods This study assessed the predictive factors of hemorrhagic pneumonia caused by SM. The medical records of patients admitted to Osaka City University Hospital with SM bacteremia between January 2008 and December 2017 were retrospectively reviewed. Patients All patients who had positive blood cultures for SM were included in this study. They were categorized into two groups: the SM bacteremia with hemorrhagic pneumonia group and the SM bacteremia without hemorrhagic pneumonia group. The clinical background characteristics and treatments were compared between these groups. Results The 35 patients with SM bacteremia included 4 with hemorrhagic pneumonia and 31 without hemorrhagic pneumonia. Hematologic malignancy (p=0.03) and thrombocytopenia (p=0.04) as well as the prior use of quinolone within 30 days (p=0.04) were more frequent in the SM bacteremia patients with hemorrhagic pneumonia than in those without hemorrhagic pneumonia. The mortality of the SM bacteremia patients with hemorrhagic pneumonia was higher than that of those without hemorrhagic pneumonia group (p=0.02). Conclusion Patients with SM bacteremia who have hematologic malignancy, thrombocytopenia, and a history of using quinolone within the past 30 days should be treated with deliberation.</description><subject>Adult</subject><subject>Bacteremia</subject><subject>Female</subject><subject>Gram-Negative Bacterial Infections - complications</subject><subject>Gram-Negative Bacterial Infections - drug therapy</subject><subject>Hematologic Neoplasms - complications</subject><subject>Hemoptysis - microbiology</subject><subject>Hemorrhage</subject><subject>Hemorrhage - microbiology</subject><subject>hemorrhagic pneumonia</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><subject>Immunocompromised hosts</subject><subject>Internal medicine</subject><subject>Male</subject><subject>Malignancy</subject><subject>Medical records</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Patients</subject><subject>Pneumonia</subject><subject>Pneumonia, Bacterial - complications</subject><subject>Pneumonia, Bacterial - drug therapy</subject><subject>Prognosis</subject><subject>quinolone</subject><subject>Quinolones - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Stenotrophomonas maltophilia</subject><subject>Stenotrophomonas maltophilia - immunology</subject><subject>Thrombocytopenia</subject><subject>Thrombocytopenia - complications</subject><subject>Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkk1v1DAQhiMEokvhLyBLXLikteMkji9IKKIUqSoVH2dr1pnseuXYi-1U2n-Po11WUC4zsuaZ1555XRSE0auKtfLauITBgZ1wMNo4vOK86UomnxUrxmtZioo3z4sVlawrqxwuilcx7ijlnZDVy-KCM1mzrpWrIvTWOKPBkn4LAXTWNTEZHYkfyTfYm8EeyEPwm4AxmkckN5AyfIuTD2ELG6PJg8N58s4A6WGOOJD1gXxP6HwKfr_1uQSRTGBTPhlr4HXxYgQb8c0pXxY_bz796G_Lu6-fv_Qf70rdtm0q1-MwwoCQJ-OsFQNoRjveQt1ghVS2IJqukmuGjRxrzSvJB6ZbXXPZYTOKml8WH466-3mdF6XRpQBW7YOZIByUB6P-rTizVRv_qASlHW1EFnh_Egj-14wxqclEjdaCQz9HVXEuhaS84Rl99wTd-XlxaKFq2QkmWpqp7kjp4GMMOJ4fw6hajFVPjVWLsYrJ3Pr272HOjX-czMD9EdjFBBs8AxCymxb_V26kqpZwuuEM6vwPFDr-GwdIxPk</recordid><startdate>20200115</startdate><enddate>20200115</enddate><creator>Imoto, Waki</creator><creator>Yamada, Koichi</creator><creator>Yamairi, Kazushi</creator><creator>Shibata, Wataru</creator><creator>Namikawa, Hiroki</creator><creator>Yukawa, Satomi</creator><creator>Yoshii, Naoko</creator><creator>Nakaie, Kiyotaka</creator><creator>Hirose, Asao</creator><creator>Koh, Hideo</creator><creator>Watanabe, Tetsuya</creator><creator>Asai, Kazuhisa</creator><creator>Nakamae, Hirohisa</creator><creator>Kaneko, Yukihiro</creator><creator>Kawaguchi, Tomoya</creator><creator>Hino, Masayuki</creator><creator>Kakeya, Hiroshi</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200115</creationdate><title>Clinical Characteristics of Rapidly Progressive Fatal Hemorrhagic Pneumonia Caused by Stenotrophomonas maltophilia</title><author>Imoto, Waki ; Yamada, Koichi ; Yamairi, Kazushi ; Shibata, Wataru ; Namikawa, Hiroki ; Yukawa, Satomi ; Yoshii, Naoko ; Nakaie, Kiyotaka ; Hirose, Asao ; Koh, Hideo ; Watanabe, Tetsuya ; Asai, Kazuhisa ; Nakamae, Hirohisa ; Kaneko, Yukihiro ; Kawaguchi, Tomoya ; Hino, Masayuki ; Kakeya, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c666t-bfdfadea3583167dac10836a45e2e096a75829b1e59f4c3293d1c6c4398e5f743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Bacteremia</topic><topic>Female</topic><topic>Gram-Negative Bacterial Infections - complications</topic><topic>Gram-Negative Bacterial Infections - drug therapy</topic><topic>Hematologic Neoplasms - complications</topic><topic>Hemoptysis - microbiology</topic><topic>Hemorrhage</topic><topic>Hemorrhage - microbiology</topic><topic>hemorrhagic pneumonia</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><topic>Immunocompromised hosts</topic><topic>Internal medicine</topic><topic>Male</topic><topic>Malignancy</topic><topic>Medical records</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Patients</topic><topic>Pneumonia</topic><topic>Pneumonia, Bacterial - complications</topic><topic>Pneumonia, Bacterial - drug therapy</topic><topic>Prognosis</topic><topic>quinolone</topic><topic>Quinolones - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Stenotrophomonas maltophilia</topic><topic>Stenotrophomonas maltophilia - immunology</topic><topic>Thrombocytopenia</topic><topic>Thrombocytopenia - complications</topic><topic>Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Imoto, Waki</creatorcontrib><creatorcontrib>Yamada, Koichi</creatorcontrib><creatorcontrib>Yamairi, Kazushi</creatorcontrib><creatorcontrib>Shibata, Wataru</creatorcontrib><creatorcontrib>Namikawa, Hiroki</creatorcontrib><creatorcontrib>Yukawa, Satomi</creatorcontrib><creatorcontrib>Yoshii, Naoko</creatorcontrib><creatorcontrib>Nakaie, Kiyotaka</creatorcontrib><creatorcontrib>Hirose, Asao</creatorcontrib><creatorcontrib>Koh, Hideo</creatorcontrib><creatorcontrib>Watanabe, Tetsuya</creatorcontrib><creatorcontrib>Asai, Kazuhisa</creatorcontrib><creatorcontrib>Nakamae, Hirohisa</creatorcontrib><creatorcontrib>Kaneko, Yukihiro</creatorcontrib><creatorcontrib>Kawaguchi, Tomoya</creatorcontrib><creatorcontrib>Hino, Masayuki</creatorcontrib><creatorcontrib>Kakeya, Hiroshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Imoto, Waki</au><au>Yamada, Koichi</au><au>Yamairi, Kazushi</au><au>Shibata, Wataru</au><au>Namikawa, Hiroki</au><au>Yukawa, Satomi</au><au>Yoshii, Naoko</au><au>Nakaie, Kiyotaka</au><au>Hirose, Asao</au><au>Koh, Hideo</au><au>Watanabe, Tetsuya</au><au>Asai, Kazuhisa</au><au>Nakamae, Hirohisa</au><au>Kaneko, Yukihiro</au><au>Kawaguchi, Tomoya</au><au>Hino, Masayuki</au><au>Kakeya, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Characteristics of Rapidly Progressive Fatal Hemorrhagic Pneumonia Caused by Stenotrophomonas maltophilia</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2020-01-15</date><risdate>2020</risdate><volume>59</volume><issue>2</issue><spage>193</spage><epage>198</epage><pages>193-198</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>Objective Hemorrhagic pneumonia due to Stenotrophomonas maltophilia (SM) in severely immunocompromised patients has a very poor prognosis. However, the risk factors for hemorrhagic pneumonia are not clear. Methods This study assessed the predictive factors of hemorrhagic pneumonia caused by SM. The medical records of patients admitted to Osaka City University Hospital with SM bacteremia between January 2008 and December 2017 were retrospectively reviewed. Patients All patients who had positive blood cultures for SM were included in this study. They were categorized into two groups: the SM bacteremia with hemorrhagic pneumonia group and the SM bacteremia without hemorrhagic pneumonia group. The clinical background characteristics and treatments were compared between these groups. Results The 35 patients with SM bacteremia included 4 with hemorrhagic pneumonia and 31 without hemorrhagic pneumonia. Hematologic malignancy (p=0.03) and thrombocytopenia (p=0.04) as well as the prior use of quinolone within 30 days (p=0.04) were more frequent in the SM bacteremia patients with hemorrhagic pneumonia than in those without hemorrhagic pneumonia. The mortality of the SM bacteremia patients with hemorrhagic pneumonia was higher than that of those without hemorrhagic pneumonia group (p=0.02). Conclusion Patients with SM bacteremia who have hematologic malignancy, thrombocytopenia, and a history of using quinolone within the past 30 days should be treated with deliberation.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>31941869</pmid><doi>10.2169/internalmedicine.3358-19</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2020/01/15, Vol.59(2), pp.193-198 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7008057 |
| source | MEDLINE; PubMed Central Open Access; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; PubMed Central |
| subjects | Adult Bacteremia Female Gram-Negative Bacterial Infections - complications Gram-Negative Bacterial Infections - drug therapy Hematologic Neoplasms - complications Hemoptysis - microbiology Hemorrhage Hemorrhage - microbiology hemorrhagic pneumonia Humans Immunocompromised Host Immunocompromised hosts Internal medicine Male Malignancy Medical records Middle Aged Original Patients Pneumonia Pneumonia, Bacterial - complications Pneumonia, Bacterial - drug therapy Prognosis quinolone Quinolones - therapeutic use Retrospective Studies Risk Factors Stenotrophomonas maltophilia Stenotrophomonas maltophilia - immunology Thrombocytopenia Thrombocytopenia - complications Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use |
| title | Clinical Characteristics of Rapidly Progressive Fatal Hemorrhagic Pneumonia Caused by Stenotrophomonas maltophilia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T15%3A38%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Characteristics%20of%20Rapidly%20Progressive%20Fatal%20Hemorrhagic%20Pneumonia%20Caused%20by%20Stenotrophomonas%20maltophilia&rft.jtitle=Internal%20Medicine&rft.au=Imoto,%20Waki&rft.date=2020-01-15&rft.volume=59&rft.issue=2&rft.spage=193&rft.epage=198&rft.pages=193-198&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.3358-19&rft_dat=%3Cproquest_pubme%3E2349871760%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2349871760&rft_id=info:pmid/31941869&rfr_iscdi=true |